Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Beclomethasone Dipropionate BAI vs MDI in Persistent Asthma
NCT02031640Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate in asthma (5 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second Area Under the Effect Curve at 12 weeks. Started Dec 2013; status: completed.
02
Drugs
beclomethasone dipropionate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02031640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031640.